Ready to go the moment permission came through
Na manhã de 19 de novembro de 2020, São Paulo recebeu 120 mil doses da CoronaVac — um dia antes do previsto — como parte de um acordo maior com a farmacêutica chinesa Sinovac. As doses chegaram prontas, mas o país ainda não estava autorizado a usá-las: a vacina aguardava a conclusão dos ensaios clínicos e a aprovação formal da Anvisa. É um momento que encapsula uma tensão antiga da história humana — a da solução que existe, mas ainda não pode ser tocada, enquanto o sofrimento continua.
- 120 mil doses da CoronaVac chegaram a São Paulo com um dia de antecedência, mas foram imediatamente guardadas em local sigiloso, inacessíveis à população.
- A vacina ainda estava em fase final de testes clínicos, com cerca de 10 mil voluntários recebendo doses ou placebo — sem aprovação da Anvisa, nenhuma seringa poderia ser aplicada.
- O Brasil acumulava casos e mortes enquanto o processo regulatório seguia seu ritmo próprio, criando uma corrida entre a urgência da pandemia e a necessidade de dados completos.
- São Paulo apostou alto: além das 120 mil doses iniciais, o estado firmou compromisso de compra de 46 milhões de doses e negociou transferência de tecnologia para produção nacional no Instituto Butantan.
- A CoronaVac disputava espaço com outros três candidatos a vacina em teste no Brasil, incluindo a Pfizer, que prometia imunizar milhões de brasileiros no primeiro semestre de 2021.
Na manhã de 19 de novembro de 2020, São Paulo recebeu as primeiras 120 mil doses da CoronaVac com um dia de antecedência. Os frascos foram levados a um local não divulgado por razões de segurança. Estavam prontos. O país, ainda não.
A vacina seguia em fase três de testes clínicos, com cerca de 10 mil voluntários participando do processo. Sem a aprovação da Anvisa, as doses permaneceriam intocadas — uma promessa guardada em câmara fria, aguardando que a burocracia regulatória dissesse sim.
A chegada antecipada revelava a dimensão da aposta de São Paulo. O estado havia firmado um acordo de compra de 46 milhões de doses com a Sinovac Biotech, parceira do Instituto Butantan, e negociado também a transferência de tecnologia para produção doméstica — uma forma de não depender indefinidamente da cadeia de produção chinesa.
Enquanto isso, o Brasil enfrentava uma pandemia em curso, com mortes e casos se acumulando a cada dia. A CoronaVac era uma entre quatro candidatas sendo testadas no país. A Pfizer também estava no horizonte. Mas naquela manhã, o que havia era um depósito cheio de potencial e uma pergunta simples: quando a aprovação viria?
On the morning of November 19th, 2020, São Paulo received its first shipment of CoronaVac doses—120,000 vials of a vaccine that did not yet exist, officially speaking. The doses had arrived a day ahead of schedule, part of a larger agreement between the state government and Sinovac Biotech, the Chinese pharmaceutical company developing the shot in partnership with Brazil's Butantan Institute. The vials were locked away in an undisclosed location for security reasons, waiting.
They would wait for permission. The vaccine was still in its final testing phase, moving through the third phase of clinical trials that would determine whether it actually worked. About 10,000 volunteers had already received either a dose of the vaccine or a placebo as part of that process. Until those trials concluded and Brazil's health regulator—the Anvisa—formally approved the vaccine for use, these 120,000 doses could not be administered to a single person. They were ready. The country was not yet allowed to use them.
The arrival was symbolic of São Paulo's bet on this particular vaccine. The state had committed to purchasing 46 million doses from Sinovac, a staggering number that reflected both confidence in the shot's eventual success and a calculation about what the state would need to vaccinate its population. Beyond the doses themselves, São Paulo had also negotiated for technology transfer—the knowledge and capability to manufacture CoronaVac domestically at the Butantan Institute, rather than remaining dependent on Chinese production indefinitely.
CoronaVac was one of four vaccine candidates being tested in Brazil at that moment. The race was on across the country and the world, with different states and nations placing their bets on different horses. Pfizer was also in the picture, proposing to vaccinate millions of Brazilians in the first half of 2021. But on this November morning, with 120,000 doses sitting in a secure warehouse in São Paulo, the immediate question was not whether the vaccine would work—that was still being determined—but when the regulatory machinery would finally turn and say yes.
The timing mattered. Brazil was deep in the pandemic, with cases and deaths mounting. Every day that approval was delayed was a day the country remained vulnerable. Yet rushing approval without complete data was its own kind of risk. The doses had arrived early, ready to go the moment permission came through. Now it was a waiting game, measured in test results and regulatory deliberation, with a warehouse full of potential sitting in the background.
A Conversa do Hearth Outra perspectiva sobre a história
Why did São Paulo move so fast to secure 46 million doses of a vaccine that hadn't been approved yet?
Because the pandemic was real and urgent, and they had to make a choice about which vaccine to bet on. If you wait until approval to negotiate, you're at the back of the line. São Paulo decided CoronaVac was worth the risk.
But what if it didn't work? What if Anvisa said no?
Then you have 46 million doses you can't use. But the state was betting on the science—the Butantan Institute had credibility, and Sinovac was already testing in multiple countries. The real gamble was on timing, not efficacy.
Why keep the location secret?
Security. You have 120,000 doses of something people desperately want. In a pandemic, that's a target. You don't advertise where it is.
The technology transfer part—what does that actually mean?
It means São Paulo isn't just buying doses. They're learning how to make them. If this works, Brazil becomes self-sufficient instead of dependent on Chinese supply chains. That's strategic thinking beyond the immediate crisis.
So this shipment arriving early—was that good news or just logistics?
Both. It meant the supply chain was working, that the partnership was solid. But it also meant you had doses sitting in a warehouse, ready to go, while you waited for bureaucracy to catch up. That's its own kind of tension.